Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 23Terminated 4Withdrawn 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 85Cyclophosphamide 74Nivolumab 58fludarabine 49Specimen Handling 49Magnetic Resonance Spectroscopy 43Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 30atezolizumab 27Gemcitabine 27Paclitaxel 26Ipilimumab 26Cisplatin 24venetoclax 23Radiation 23Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Temozolomide 18Lenalidomide 18Bevacizumab 17palbociclib 15Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Carmustine × Clear all
NCT01840566 2025-12-03

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡